Last update 20 Jun 2024
Dextrose
Last update 20 Jun 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Distal jejunal-release dextrose beads, Glucose, ブドウ糖 + [7] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (25 Jan 1971), |
Regulation- |
Login to view First Approval Timeline
Structure
Molecular FormulaC6H12O6 |
InChIKeyGZCGUPFRVQAUEE-SLPGGIOYSA-N |
CAS Registry50-99-7 |
Related
229
Clinical Trials associated with DextroseThe Low-Dose Interleukin-2 For The Reduction Of Vascular Inflammation In Acute Coronary Syndromes -Clinical Outcomes And Follow-up Study
Phase I Study of the Safety and Feasibility of a Ketogenic Dietary Intervention to Improve Response to Immunotherapy
Comparative Study of Intraarticular Erythropoietin and Dextrose Prolotherapy in Knee Osteoarthritis
100 Clinical Results associated with Dextrose
Login to view more data
100 Translational Medicine associated with Dextrose
Login to view more data
100 Patents (Medical) associated with Dextrose
Login to view more data
5,272
Literatures (Medical) associated with Dextrose01 May 2024Food chemistry
Insight into the effect of osmosis agents on macro- and micro- texture, water distribution, and thermal stability of instant controlled pressure drop drying peach chips
Article
Author: Wang, Fengzhao ; Bi, Jinfeng ; Lyu, Mingyue ; Lyu, Jian
To investigate the influence of sugar structure on the quality of peach chips produced using osmotic dehydration (OD) in combination with instant controlled pressure drop (DIC) drying, erythritol, glucose, maltose, and trehalose were selected as osmotic agents. The properties of the osmotic solutions, as well as the macro- and micro-texture, water distribution, and thermal stability of peach chips were investigated. Results showed that OD pretreatments inhibited the formation of large cavity structures. The highest hardness (101.34 N) and the lowest hydrophobicity (0°) were obtained in erythritol-OD samples. Trehalose-OD samples with the most homogeneous pore structure exhibited the highest crispness (1.05 mm) and the highest glass transition temperature (52.06 °C). Various absorption peaks of peach chips pretreated with different OD methods, characterized by Raman spectroscopy, suggested changes in composition and functional groups due to the diffusion of sugars into the cells of peach tissues, which also contributed to the higher Tg.
01 Apr 2024Journal of pharmaceutical and biomedical analysis
Efficient and straightforward spectrophotometric analysis of 5-hydroxymethylfurfural (HMF) using citrate@Fe3O4 nanoparticles as an adsorbent
Article
Author: Zamani-Kalajahi, Monireh ; Monajjemzadeh, Farnaz ; Hamidi, Samin ; Abdollahi, Kolsoum ; Nemati, Mahboob ; Sheykhizadeh, Saheleh
In this study, we developed a spectrophotometry method for the analysis of 5-hydroxymethylfurfuraldehyde (HMF) in pharmaceutical formulations using citrate@Fe3O4 adsorbent. As bare magnetite (Fe3O4) has certain limitations, such as aggregation and oxidation, surface modifications are commonly used to improve its properties. We successfully coated Fe3O4 with sodium citrate to create a magnetic adsorbent for isolating HMF from samples. We confirmed the successful surface coating of Fe3O4 with citrate using Fourier Transform infrared spectroscopy (FT-IR), X-ray diffraction (XRD), Zeta potential, and scanning electron microscopy (SEM). The high adsorption capacity of citrate@Fe3O4 is due to the abundance of carboxyl and hydroxyl groups on the surface of the adsorbent, making it ideal for HMF extraction. The HMF concentration was then quantified using spectrophotometry. Citrate@Fe3O4 exhibited a high surface area and strong interaction with HMF. We analyzed the individual influential factors affecting the magnetic solid phase extraction (MSPE) setup. Validation parameters were also provided to confirm the reliability of the method. Under optimal parameters, the method exhibited excellent linearity in the range of 0.05-30.00 μg/ml with the lower limit of quantification (LLOQ) of 0.05 μg/ml. Relative standard deviations (RSD) values for precision were better than 10% and the method's trueness were better than 10%. Recoveries were found to be in the range of 85% to 106%, indicating excellent accuracy and reliability. We used this method to identify and measure HMF in six different dextrose pharmaceutical dosage forms as intravenous injectable solutions and three honey samples.
Archives of disease in childhood. Fetal and neonatal edition
Dextrose gel prophylaxis for neonatal hypoglycaemia and neurocognitive function at early school age: a randomised dosage trial
Article
Author: Harding, Jane E ; Wouldes, Trecia A ; Gamble, Gregory D ; Thompson, Benjamin ; McKinlay, Christopher J D ; Turuwhenua, Jason ; Brown, Gavin T L ; Franke, Nike ; McNeill, Alicia ; Rogers, Jenny ; Wei, Xingyu ; Alsweiler, Jane M
Objective:
To investigate the effect of different doses of prophylactic dextrose gel on neurocognitive function and health at 6–7 years.
Design:
Early school-age follow-up of the pre-hPOD (hypoglycaemia Prevention with Oral Dextrose) study.
Setting:
Schools and communities.
Patients:
Children born at ≥35 weeks with ≥1 risk factor for neonatal hypoglycaemia: maternal diabetes, small or large for gestational age, or late preterm.
Interventions:
Four interventions commencing at 1 hour of age: dextrose gel (40%) 200 mg/kg; 400 mg/kg; 200 mg/kg and 200 mg/kg repeated before three feeds (800 mg/kg); 400 mg/kg and 200 mg/kg before three feeds (1000 mg/kg); compared with equivolume placebo (combined for analysis).
Main outcomes measures:
Toolbox cognitive and motor batteries, as well as tests of motion perception, numeracy and cardiometabolic health, were used. The primary outcome was neurocognitive impairment, defined as a standard score of more than 1 SD below the age-corrected mean on one or more Toolbox tests.
Findings:
Of 392 eligible children, 309 were assessed for the primary outcome. There were no significant differences in the rate of neurocognitive impairment between those randomised to placebo (56%) and dextrose gel (200 mg/kg 46%: adjusted risk difference (aRD)=−14%, 95% CI −35%, 7%; 400 mg/kg 48%: aRD=−7%, 95% CI −27%, 12%; 800 mg/kg 45%: aRD=−14%, 95% CI −36%, 9%; 1000 mg/kg 50%: aRD=−8%, 95% CI −29%, 13%). Children exposed to any dose of dextrose gel (combined), compared with placebo, had a lower risk of motor impairment (3% vs 14%, aRD=-11%, 95% CI −19%, −3%) and higher mean (SD) cognitive scores (106.0 (15.3) vs 101.1 (15.7), adjusted mean difference=5.4, 95% CI 1.8, 8.9).
Conclusions:
Prophylactic neonatal dextrose gel did not alter neurocognitive impairment at early school age but may have motor and cognitive benefits. Further school-age follow-up studies are needed.
8
News (Medical) associated with Dextrose02 May 2024
100 Deals associated with Dextrose
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Water-Electrolyte Imbalance | US | 25 Jan 1971 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Glucose Intolerance | Phase 2 | US | 01 Apr 2023 | |
| Prediabetic State | Phase 2 | US | 01 Apr 2023 | |
| Obesity | Phase 2 | DE | 01 Jul 2022 | |
| Obesity | Phase 2 | PR | 01 Jul 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 12 | (Parenteral Nutrition Energy Dose at 0.6 x Measured REE) | pdxvdxkqzs(bydpnqvytu) = sdtmpqrmyf azgtkttdfr (yicmiqkppm, qbhyilclvx - etccdrihqb) View more | - | 10 Jun 2022 | ||
(Parenteral Nutrition Energy Dose at 1.0 x Measured REE) | pdxvdxkqzs(bydpnqvytu) = pefmpzwrxy azgtkttdfr (yicmiqkppm, tdaxauzebg - bcdstopjzn) View more | ||||||
Not Applicable | 10 | nlfdiztnuy(kssubcheuk) = sxbntecqlf ssnaooujwd (cdsygdxlrq ) View more | - | 01 Jun 2021 | |||
Not Applicable | fasting plasma glucose | fasting plasma insulin | HOMA-IR ... View more | 436 | Gelesis100 | wkyctqrzfq(ryuzoiiivr): mean difference = 0.1 (95% CI, 0.02 - 0.17), P-Value = 0.011 | - | 04 Nov 2020 | |
Placebo | |||||||
Not Applicable | 142 | kdjaeghitn(lxeupslsgw) = oalhocvhkr jidkmzbwlb (elalqrcola, 1.67 - 16.0) View more | Positive | 05 Nov 2019 | |||
Not Applicable | 60 | (Patients with LCHADD) | lvodexucbr(akkhsaxyty) = kfqvwpgaxn acrgbcowiv (ivfmkfvpvp ) | - | 01 Sep 2019 | ||
(Healthy persons) | lvodexucbr(akkhsaxyty) = uwsdraaaci acrgbcowiv (ivfmkfvpvp ) | ||||||
Phase 2/3 | 32 | vzkdkqldoo(nxolfsicgw) = zfhhsrwdkq rtbpnpueuz (waovhvdndt ) | Positive | 01 Dec 2018 | |||
Not Applicable | 90 | placebo+methamphetamine (Paired, Low Reward) | kamcmmpjzv(nuwtowwjcf) = xvheltxgjd memyvsmlci (jkqcgicglb, wrbawxrirx - zjkfpawxss) View more | - | 26 Jul 2018 | ||
placebo+methamphetamine (Paired, High Reward) | kamcmmpjzv(nuwtowwjcf) = exsvyfdspn memyvsmlci (jkqcgicglb, tdrgogyqkr - rlnggnqlff) View more | ||||||
Phase 4 | 115 | Glucose (Glucose) | jpzvaamtgx(qmffteywwf) = wwppalyobm unyumijklj (klpprvvscl, pgldxnubey - nljquzwtjd) View more | - | 28 Nov 2017 | ||
(Polidocanol With Glucose) | jpzvaamtgx(qmffteywwf) = iblnihtikr unyumijklj (klpprvvscl, idckuppmfg - liafynxxar) View more | ||||||
Phase 4 | 106 | (Polidocanol With Glucose) | wlbjgjqdcj(dtzzoszqzb) = bqwwgtfehl hxecnnfwag (sytdjgvhku, vusvvvaqkh - edqwlalknm) View more | - | 27 Jan 2017 | ||
Glucose (Glucose) | wlbjgjqdcj(dtzzoszqzb) = qtuntrdpvl hxecnnfwag (sytdjgvhku, dhqcexeafo - oqejdslxns) View more | ||||||
Not Applicable | 35 | tgbwnwsfcf(mjyebcxbme) = qwqnoniaxl moqpcsdojo (cdzirolewq ) View more | - | 06 Dec 2016 | |||
0.9% Saline | tgbwnwsfcf(mjyebcxbme) = wyejqoynhm moqpcsdojo (cdzirolewq ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free